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68 S. Elkaradawy et al.IL-1b were measured before operation, 1, 3, 6 & 9 months, postoperatively. Their relationship with
neuropathic pain was assessed.
Results: Nociceptive pain was less in intervention group than control group immediately post oper-
ative, 4 h after surgery at rest and 8 h with movement. Neuropathic pain started few days postop-
eratively, in both groups. Its onset, sites, duration and precipitating factors did not differ between
the groups. Sensitive, hot pain and unpleasantness reduced signiﬁcantly 1 month postoperatively, in
intervention group. Two months later, itchy, dull and sharp pain was signiﬁcantly less in interven-
tion group. At 6 months, most of neuropathic pain items except sharp and deep pain lowered sig-
niﬁcantly in intervention group. At 9 months, hot and superﬁcial pain was still less in intervention
group. NO decreased signiﬁcantly 1 and 3 months postoperatively, while IL-1b was signiﬁcantly
lower through different times, in intervention group. IL-1b correlated well with neuropathic pain
intensity and unpleasantness.
Conclusion: Breast surgery for cancer was associated with neuropathic pain that continued for
9 months after surgery. Multimodal balanced GA had positive impact on acute nociceptive and
neuropathic pain. Gabapentin reduced almost all neuropathic pain qualities.
ª 2011 Egyptian Society of Anesthesiologists. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Neuropathic pain following breast cancer surgery was thought
to be rare. Accordingly, its prevention and management was
neglected for a long time. The results of late studies suggested
that, neuropathic pain following breast surgery was acute in
nature, then progressed to persistent or chronic pain in 50%
of the patients. Thirty percent of those patients reported no
change or worsening of their neuropathic pain symptoms
[1,2]. This ﬁnding might change physicians’ attitude towards
the management of postoperative neuropathic pain [3].
Neuropathic pain reported by patients can be transient or
long-lasting, and has different expressions such as burning
pain, numbness, pin prick, phantom sensations, and sensory
loss or changes. According to the site of pain, four different
types were identiﬁed; intercostobrachial neuralgia (ICN) or
post-mastectomy pain syndrome, which is deﬁned as pain
accompanied by sensory changes in the distribution of the int-
ercostobrachial nerve following breast surgery with or without
axillary dissection, neuroma pain or scar pain (pain in the re-
gion of a scar on the breast, chest, or arm that is provoked or
exacerbated by percussion), phantom breast pain (a sensory
experience of a removed breast that is still present and is pain-
ful) and other neuropathic pain (pain outside the distribution
of the intercostobrachial nerve consistent with damage to other
nerves during breast surgery) [4,5].
Chemotherapy and radiotherapy can be additional risk fac-
tors for developing neuropathic pain and related symptoms
and make diagnosis more difﬁcult [6]. Persistent pain can be a
source of considerable disability and psychological distress for
patients. For example, it may lead to limited daily activity, sleep
disturbance, persistent symptoms of depression and anxiety.
These consequences reﬂect negatively on family and social life [7].
To date, the mechanism of neuropathic pain following
breast therapy is still poorly understood. Recent investigations
on chronic post surgical pain revealed that, both post surgical
prolonged inﬂammation and excessive stretching and injuries
to the nerves may lead to over stimulation of the spinal cord
and result in central sensitization [8]. In inﬂammatory type
of pain, local inﬂammatory mediators released from injured
tissue stimulate peripheral sensory neurons. These in turn, pro-
duce repetitive ﬁring to modulate and exaggerate dorsal hornmediators. Modulation at the level of spinal cord is not a sim-
ple process; it needs abnormal expression of transcription fac-
tors that alter the function of ion channels and receptors.
Subsequent alteration in protein transcription in sensory neu-
rons and in the spinal cord augments the release of excitatory
transmitters and decreases inhibitory mediators resulting in
central sensitization and spreading of spontaneous ongoing
pain [9]. Concurrent nerve injuries during surgery produce cen-
tral sensitization through structural and functional neural
changes. Structure changes are due to direct nerve injury or
formation of neuroma (entangling of nerve ﬁbers into sur-
rounding tissue), while functional changes are developed as a
result of proliferation and activation of both tetrodotoxin sen-
sitive and -resistant sodium channels following nerve injury
that stimulate the release of excitatory mediators [10].
A growing body of evidence suggests that, nitric oxide (NO)
and cytokines may be the main inﬂammatory mediators
responsible for maintenance and exaggerating pain states after
breast therapy [11]. Nitric oxide is an intracellular mediator
responsible for numerous physiological processes in human
body. It can exert pro- or anti-nociceptive effects depending
on its concentration. Anti-nociceptive effects were evident in
several animal studies when NO was injected in small amounts
with NSAIDs [12,13]. On the other hand, pronociceptive ef-
fects were obvious when noxious stimuli induced signiﬁcantly
increased NO levels, either locally and at central levels. This
pronociceptive effect was antagonized by NOS inhibitors
[14,15].
Similarly, a number of pro and anti inﬂammatory cytokines
are released in response to painful stimuli. Pro-inﬂammatory
cytokines, such as tumor necrosis factor (TNF) and interleu-
kin-1 beta (IL-1b), reduce thermal or mechanical pain thresh-
olds, while anti-inﬂammatory ones, such as IL-4, IL-10, and
IL-13 inhibit the production and action of the pro-inﬂamma-
tory cytokines and possess anti hyperalgesic effect. The imbal-
ance between both is responsible for pathological states [16].
To date, there is no evidence-based protocol for the
management of chronic post breast therapy pain. Successful
prevention and effective management may depend on minimiz-
ing risks for developing this type of pain. Psycho-education
program, as well as encouraging family support may reduce
the risk [17]. On the hand, better control of perioperative pain
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gional and general balanced analgesia [18], in addition to
attenuation of acute neuropathic pain intensity using analge-
sics, may reduce the incidence of developing persistent post
operative pain [19].
Gabapentin [1-(aminomethyl) cyclohexane acetic acid], a
structural analogue of c-aminobutyric acid (GABA), was
introduced as an antiepileptic drug, and is extensively used
in the treatment of neuropathic pain. Gabapentin has been
shown to reduce analgesic requirements for acute postopera-
tive pain [20].
The present study aimed to evaluate the effect of multi-
modal balanced anaesthesia and long term use of gabapentin
(6 months) on neuropathic pain intensity and its mediators;
NO and IL1-b.
2. Patients and methods
After obtaining Ethical Committee approval and taking pa-
tients’ consents, this study was conducted on 50 female pa-
tients between 20 and 59 years of age, admitted to the
Clinical Surgery Department, Medical Research Institute Hos-
pital, Alexandria University. All patients underwent surgical
excision of tumor with adequate safety margin and axillary
clearance, followed by either chemo and/or radiotherapy.
After premedication with midazolam (0.01–0.04 mg/kg) intra-
venously, patients were divided into two groups. Patients in
control group received the standard general anaesthesia, while
those in the intervention group received multimodal balanced
anaesthesia (US guided paravertebral block followed by the
standard general anaesthesia). Three patients in control group
and four patients in intervention group refused to continue in
the research.
2.1. Inclusion and exclusion criteria
All patients were American Society of Anesthesiologists phys-
ical status II (ASA 11), and underwent conservative breast sur-
gery for cancer. Patients with chronic pain, consuming
analgesics, antidepressants, calcium channel blockers, antiepi-
leptics, sedatives, hypnotics or received radiotherapy and/or
chemotherapy prior to surgery were excluded from the study.
Other exclusion criteria were submission to previous breastSkin 
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Spine process
LaminaTransverse process
T
P
Pleura
Figure 1 Ultrasound image of 3rd thorasurgical operation, evidence of metastasis or refusing to give
consent.
2.2. Anaesthesia
Ultrasound guided paravertebral block (PVB) was performed
using SonoSite, S nerve, 2 D, Inc., USA machine and 60 mm
curved probe 5–12 MHZ. The block was done in the sitting po-
sition using touhy needle 18 G and catheter 19 G at the level of
ipsilateral 3rd thoracic vertebra Figs. 1 and 2. Twenty-ﬁve mil-
liliter bupivacaine 0.25% was injected in paravertebral space at
the ipsilateral site of surgery. Ipsilateral sensory block was as-
sessed, 5–10 min after bupivacaine injection, at 2nd to 6th tho-
racic vertebrae by absent sensation to cold.
General anaesthesia in both groups was introduced by
fentanyl 2 lg/kg, propofol 1–2 mg/kg, and cisatracurium
0.15 mg/kg for facilitation of tracheal intubation. Anaesthesia
was maintained with isoﬂurane1–2%, air–oxygen mixture, and
morphine 0.05 mg/kg/h intravenously. Cisatracurium 0.05 mg/
kg was given to maintain one twitch of train of four using
nerve stimulator. Postoperative pain was controlled using i.v
acetaminophen (1 g/6 h) for 3 days, in addition to either i.v
morphine PCA (Master PCA Fresenius KABI) at concentra-
tion of 1 mg/ml using 3 ml loading dose and 1 ml PCA with
lock out time 6 min and a 20 ml maximum dose/4 h for 24 h
in the control group or paravertebral PCA bupivacaine
0.125%, using 8 ml loading dose and a 6 ml/h infusion with
a 4 mL bolus and 15-min lockout for 24 h, in the intervention
group. Before discharging home, all patients were instructed
to note the pain they might have at home and record the
analgesic consumption. Non steroidal anti-inﬂammatory
drugs (Meloxicam; 15 mg, once/day) and anti-inﬂammatory
enzymes (Trypsin or Chymotrypsin, one tablet, three times/
day, taken 1 h prior to meal) were prescribed to each patient
for 10 days, postoperatively. Gabapentin was prescribed to
any patient reporting neuropathic pain (VASP 4/10 points)
1 month after surgery and for 6 months in the intervention
group. Gabapentin (300 mg, orally in divided doses) was given,
and titrated up to 100 mg daily, to decrease pain intensity to
less than four points (on scale 0–10 cm). Gabapentin maxi-
mum dose was 1800 mg. If excessive sedation, drowsiness or
dizziness was reported, gabapentin was reduced to the previous
dose.ransverse process
leura
Paravertebral 
space
cic vertebra and paravertebral space.
Spread of local anaesthetic
Needle
Pleura
Transverse process
Local anaesthetic
Figure 2 Local anaesthetic injection and its spread into paravertebral space.
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Using NCSS software, a sample size of 20 in each group was
able to detect a difference of 1.00 ± 0.5 in pain scale of 0–10
points between the control and the intervention group with
90% power and at 5% level of signiﬁcance.
2.4. Measurements
2.4.1. Outcome measures
The primary outcome was to detect the incidence of neuro-
pathic pain after breast therapy for cancer. Secondary out-
come was to measure the effect of multimodal balanced
anaesthesia and gabapentin on the intensity and characters
of neuropathic pain and its mediators.
2.5. Acute pain
 Acute postoperative pain after conservative breast surgery
for cancer was evaluated using visual analogue scale
(VAS) 0–10 cm with 0 = no pain and 10 = worst possible
pain experienced. It was measured immediately after anaes-
thetic recovery at rest, then every 4 h for 24 h during rest
and movement of ipsilateral arm.
 Additional analgesics taken after 10 days postoperatively
were recorded.
2.6. Evaluation and measurement of neuropathic pain
Criteria for diagnosis of neuropathic pain were; presence of
burning sensation, tingling, numbness, sensory loss, hyperalge-
sia and/or allodynia at ipsilateral breast or arm. Neuropathic
pain was evaluated using pain questionnaire [21], neuropathic
pain scale (NPS) [22] and sensory examination. The question-
naire assessed pain character, onset, location and duration of
pain. It also evaluated a number of precipitating factors of pain
and effect of pain on activity, sleep andmood (each itemwas rat-
ing on scale 0–4). (Appendix A) The NPS contains an introduc-
tion describing how people may experience pain sensations
differently and how unpleasantness differs from intensity. The
scale presents 10 domains of pain, including two items that as-
sess global pain; pain intensity and pain unpleasantness and
eight items that assess the speciﬁc qualities of neuropathic pain:sharp, hot, dull, cold, sensitive, itchy, deep, and surface. Patients
were asked to rate each quality of pain on a scale of 0–10, where
0 = no pain and 10 the worst sensation imaginable. (Appendix
B) NPS was evaluated at 1, 3, 6 and 9 months, postoperatively.
Sensory examination was performed for surgical and contralat-
eral side to conﬁrm the neuropathic nature of pain. It was con-
ducted to evaluate hypothesia, hyperalgesia and/or allodynia on
area around breast scar, axillary scar and inner aspect of ipsilat-
eral arm (distribution of intercostobrachial nerve) and/or outer
aspect of arm (distribution of other nerves). Absent sensation to
ﬁne touch (piece of cotton) was used to detect hypothesia. Pain
on slight touch to skin or repeated brushing of the skin indicated
allodynia. Exaggerated response to pin prick sensation or cold
sensation (alcohol swab) in comparison to other arm showed
hyperalgesia.
2.7. Measurement of pain mediators
Venous blood samples were withdrawn from all patients par-
ticipating in the current study, 1 day prior to operation and
1, 3, 6 and 9 months after operation for NO levels and IL1-b
measurements. Blood samples were centrifuged and serum
was collected and stored 50 C till assay time. Plasma ni-
trate/nitrite (NOx) content was determined using Griess reac-
tion [23]. Serum IL1-b was measured using sandwich ELISA
technique [24].
2.8. Difﬁculties encountered
At the beginning, this study aimed to evaluate the effect of
continuous use of preemptive gabapentin for 6 months on
the severity of post breast therapy neuropathic pain and its
mediators; NO level and IL-1b. Since neuropathic pain started
during gabapentin intake, patients did not believe in gabapen-
tin efﬁcacy and consequently discontinued treatment. It was
easier to prescribe it after neuropathic pain perception to de-
crease its intensity.
2.9. Statistical analysis
Statistical analysis was performed using SPSS version 18.0.
Normality testing was done through the Kolmogrov–Smirnov
test. Normally distributed quantitative variables were de-
scribed by mean and standard deviation, while not normally
distributed data were described through the median and range.
Figure 3 Pain at rest during the ﬁrst 24 h post operative.
Figure 4 Pain at ipsilateral arm movement during the ﬁrst 24 h
post operative.
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%. Comparisons between the control and the intervention
group were done through the independent t-test for normally
distributed quantitative variables, while the Mann Whitney
test was used for not-normally distributed variables. Qualita-
tive variables were compared using the chi-squared test. In case
of invalid Chi-square, the MonteCarlo p value was used. Cor-
relations between pain scales, global items and the neuropathic
pain mediators were done through the Spearman’s rank corre-
lation coefﬁcient. All tests were two-sided and the signiﬁcance
was set at 5% level.
3. Results
Patients’ characteristics were matched in both studied groups.
No statistically signiﬁcant differences were present between
groups, neither in age, body weight, surgical duration, nor in
type of therapy following surgery Table 1.
Acute nociceptive pain following surgery was reported by
the patients in both studied groups at the breast, axilla and
ipsilateral shoulder. Pain intensity measured by VAS at rest
was less in the intervention group than control group, immedi-
ately post operative and 4 h later. However, pain was less dur-
ing the ﬁrst 8 h after surgery with the movement of ipsilateral
arm Figs. 3 and 4.
One month after breast surgery, all women (100%) in both
studied groups had abnormal sensation on the breast, axilla or
the ipsilateral arm and described it as burning, tingling, numb-
ness, hypersensitivity and/or dull pain. No one reported loss of
sensation. They discovered the sensory loss in breast area, ax-
illa and inner or outer aspect of arm during sensory examina-
tion. Pain started at average on the 10th or 11th day. The most
common site of pain was ipsilateral arm in both studied
groups. The distribution of acute neuropathic post surgical
pain according to its onset sites and duration did not show sig-
niﬁcant differences between the control and intervention
groups. Similarly, effort, hotness and/or coldness, that precip-
itated pain, pain interfered with activity, sleep and mood and
meloxicam consumption at 1 month postoperative, did not dif-
fer in the studied groups Table 2.
Distribution of chronic neuropathic pain according to its site
9 months after breast surgery, showed that there was a large
number of patients still complaining of pain, in both studied
groups. Thirty-nine percent of patients in both groups were
complaining of pain in the breast, meanwhile 27.9% of patients
were complaining of pain in the axilla. Pain in the arm was pres-
ent unfortunately in 72.1%, in both groups Table 3.
The global pain items of the neuropathic pain scale (pain
unpleasantness and pain intensity) showed signiﬁcantly lowerTable 1 Patients’ characteristics in the control and the intervention
Control (n
Age in years (means ± SD) 42 ± 8.1
Weight in kg (means ± SD) 75 ± 18
Duration of surgery in min. (means ± SD) 95 ± 13.9
m Type of post-surgical therapy (%)
Radiotherapy 2 (9.1)
Chemo and radiotherapy 20 (90.9)
m MonteCarlo p.values in patients in the intervention group than those in the
control group. For pain unpleasantness, signiﬁcant lower med-
ian values were found after 1 month, 3 months and 6 months,
postoperatively. Concerning pain intensity, signiﬁcant lower
median values existed, a little bit later, after 3 months, 6 and
9 months, postoperatively Table 4.
Some neuropathic pain characters were also signiﬁcantly
lower in the intervention group than in the control group (Ta-
ble 4). One month after surgery, median values for sensitive
and hot pain were signiﬁcantly lower in the intervention than
that of the control group. Two months later, median values
for itchy pain, dull pain and sharp pain were signiﬁcantly less
in the intervention group. After 6 months most of neuropathic
pain items, except sharp and deep pain were signiﬁcantly lowergroups.
= 22) Intervention (n= 21) p
41 ± 8.4 0.68
76 ± 15 0.51
90 ± 10.3 0.22
1 (4.8) 1.00
20 (95.2)
Table 2 Neuropathic pain characteristics, precipitating factors and meloxicam consumption 1 month after breast surgery.
Variables Control group Intervention group p
Number of patients reported abnormal sensation as a result of surgery (%) 22 (100%) 21 (100%) 1.00
Start of pain after surgery in days (means ± SD) 11.43 ± 3.58 9.90 ± 3.47 0.17
Site of pain (n) (%)
Breast 10 (25.0) 11 (26.8) 0.65
Arm 17 (42.5) 16 (39.0) 0.93
Axilla 13 (32.5) 14 (34.2) 0.61
Duration of pain (h) (means ± SD) 2.45 ± 0.92 2.24 ± 0.89 0.44
m Precipitating factors
Eﬀort 2 (1–3) 2 (1–3) 0.61
Hotness 2 (1–3) 2 (1–3) 0.63
Coldness 2 (1–2) 2 (1–2) 0.56
m Interference with work 2 (1–3) 2 (1–2) 0.51
With sleep 2 (1–3) 2 (1–3) 0.63
With mood 2 (1–3) 2 (1–3) 0.62
Meloxicam rescue doses (mg) (means ± SD) 78 ± 29 65 ± 27 0.14
m Values are expressed as median (range).
Table 3 Site of neuropathic pain 3, 6 and 9 months after breast surgery in the control and the intervention groups.
Pain site Control group (n= 22) Intervention group (n= 21) p Value
Breast
3 months 11 (50.0) 10 (47.6) 0.65
6 months 10 (45.5) 10 (47.6) 0.89
9 months 8 (36.4) 9 (42.9) 0.66
Axilla
3 months 11 (50.0) 11 (52.4) 0.88
6 months 7 (31.8) 9 (42.9) 0.45
9 months 7 (31.8) 5 (23.8) 0.44
Arm
3 months 17 (77.3) 16 (76.2) 0.93
6 months 15 (68.2) 16 (76.2) 0.56
9 months 15 (68.2) 16 (76.2) 0.56
Values are expressed as frequencies and %.
72 S. Elkaradawy et al.in the intervention group. At 9 months postoperatively, hot
and superﬁcial pain were still less in the intervention group.
None of the patients reported cold pain sensation.
Neuropathic pain mediators NO and IL-1b were signiﬁ-
cantly lower in the intervention group than in the control
group (Table 5). For NO, signiﬁcant lower values were de-
tected after 1 and 3 months. Meanwhile, IL-1b median values
were signiﬁcantly lower in the intervention group through the
different times.
The correlation between pain as represented by global pain
unpleasantness, pain intensity and chronic pain mediators (NO
and IL-1-b) were illustrated in Table 6. A signiﬁcant direct cor-
relation between pain unpleasantness and interleukin 1b was
found after 3 and 6 months. Similarly, a signiﬁcant direct cor-
relation between pain intensity and IL-1-b was observed after
3, 6 and 9 months.
4. Discussion
Neuropathic post-surgical pain is inﬂuenced by two mecha-
nisms: inﬂammatory mediators, which is the consequence oftrauma to peripheral tissues and intraoperative nerve damage
arising from nerve trans-section, crushing or other nerve in-
jury. Both mechanisms result in changes in the sensitivity of
the central nervous system that ampliﬁes the peripheral signal
and produces spontaneous ongoing pain. Neuropathic changes
after tissue trauma seems to be short-lived and preventable,
while those after nerve injuries are long lasting and need
aggressive strategy for prevention and treatment [24]. Nowa-
days, it has been suggested that multimodal balanced anaes-
thesia using different classes of analgesic agents with
different routes of administration can prevent neuroplastic
changes after surgical peripheral tissue trauma and attenuate
central neural excitation following nerve injuries [25].
The present study showed that acute pain after breast sur-
gery for cancer was less in intervention group at rest for 4 h
postoperatively and at movement of ipsilateral arm up to
8 h, postoperatively. This signiﬁcantly lowered pain intensity
could be explained by the effect of multimodal balanced anaes-
thesia using PVB in combination with traditional intraopera-
tive opioid analgesics that was used in the intervention
group. Paravertebral block provided tense block of dorsal root
Table 4 The neuropathic pain scale (NPS) (0–10 cm) in the control and the intervention groups at different times after breast surgery.
Neuropathic pain scale Control (n= 22) Intervention (n= 21) p value
Unpleasantness
1 month 5 (3–7) 4 (2–7) 0.05*
3 months 4 (3–8) 3 (0–6) 0.01*
6 months 4.5 (0–6) 3 (0–5) 0.00*
9 months 3 (2–5) 3 (0–4) 0.09
Intensity
1 month 5 (3–7) 4 (3–7) 0.23
3 months 5 (3–7) 3 (0–5) 0.00*
6 months 4.5 (3–6) 3 (0–4) 0.00*
9 months 4 (2–7) 3 (2–3) 0.00*
Itchiness (poison oak/mosquito bite
1 month 5 (3–7) 5 (3–7) 0.27
3 months 5 (2–6) 3 (0–5) 0.01*
6 months 0 (0–5) 0 (0–3) 0.05*
9 months 0 (0–0) 0 (0–0) 1.01
Sensitivity (sun burn/raw skin)
1 month 6 (3–7) 5 (3–7) 0.03*
3 months 3 (2–6) 4 (0–5) 0.99
6 months 3 (1–5) 2 (0–4) 0.00*
9 months 0 (0–3) 0 (0–3) 0.12
Dullness (dull toothache/dull pain/aching/bruise)
1 month 5 (4–7) 5 (3–7) 0.06
3 months 5 (2–7) 4 (2–5) 0.05*
6 months 4 (0–6) 3 (0–5) 0.00*
9 months 3 (0–3) 3 (0–3) 0.19
Sharpness (knife/spike/jabbing/jolts)
1 month 6 (3–8) 5 (4–8) 0.32
3 months 5 (3–7) 4 (3–6) 0.02*
6 months 4 (2–5) 3 (2–5) 0.32
Hotness (burring – ﬁre)
1 month 3 (2–5) 3 (2–4) 0.00*
9 months 3 (2–4) 3 (0–4) 0.00*
Superﬁcial
1 month 7 (5–10) 6 (5–10) 0.07
3 months 5.5 (5–9) 4 (3–8) 0.00*
6 months 4.5 (2–6) 3 (1–6) 0.00*
9 months 3 (1–3) 1 (1–3) 0.00*
Deep
1 month 3 (1–3) 3 (1–3) 0.3
3 months 3 (3–4) 3 (2–4) 0.32
6 months 3 (1–5) 3 (1–5) 0.51
9 months 4 (3–6) 3 (2–5) 0.23
* P 6 0.05 for Mann Whitney was considered statistically signiﬁcant. Values expressed as median (range).
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nerves in paravertebral space. Subsequently, it prevented sen-
sitization of the central nervous system, N-methyl-D-aspartate
receptor activation and inhibited ‘wind up’ phenomena [26].
Opioids are power analgesics acting on opioid receptors,
peripherally and at the central level and add synergistic analge-
sic effect [27].
In consistence with the present result, Dabbagh and Elyasi
[28] and El Nasr et al. [29] reported that the thoracic PVB pro-
vided lower visual analogue scale (VAS) for pain than did GA,
for the ﬁrst 6 h, postoperatively. Previous meta analysis study
evaluated ﬁfteen randomized control researches, including 877
patients and concluded that thoracic PVB alone or in combi-nation with GA reduced severity of postoperative pain at less
than 2 h and provided better postoperative pain relief at 2–
24 h, with little complications than general anaesthesia [30].
In the current study, better postoperative pain control un-
der the inﬂuence of multimodal balanced anaesthesia did not
give a positive impact on meloxicam consumption 1 month
after surgery. This could be explained by the developing of a
new pain (neuropathic pain) a few days after surgery, that
did not respond to meloxicam treatment. In agreement with
the present result, Kairaluoma et al. [31] reported that preop-
erative PVB did not reduce 14-day consumption of analgesics,
but it lowered the intensity of chronic pain as late as 1 year
after breast cancer surgery.
Table 5 Nitric oxide (NO) and interleukin 1 b – (IL 1-b) in the control and the intervention groups at different times, after breast
surgery.
Chronic pain mediators Control (n= 22) Intervention (n= 21) p
Nitric oxide
mPre operative 2.5 ± 0.54 2.6 ± 0.41 0.37
m1 month 4.0 ± .86 3.2 ± .74 0.00*
3 months 4.7 (2.9–6.9) 3.5 (2–4.1) 0.00*
m6 months 2.5 ± .50 2.5 ± .46 0.82
m9 months 3.4 ± .89 3.1 ± .64 0.36
Interleukin1-B
mPre operative 8.6 ± 3.91 9.2 ± 2.88 0.59
1 month 11 (6–32) 5 (1–12) 0.00*
3 months 8 (5–25) 4 (2–12) 0.00*
6 months 7 (2–10) 2 (2–6) 0.00*
9 months 5 (2–12) 3 (2–5) 0.00*
m Values expressed as mean ± SD.
* P 6 0.05 for Mann Whitney was considered statistically signiﬁcant. Values are expressed as median (range).
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gery was moderate in intensity and intermittent in duration, in
both studied groups. This moderate neuropathic pain intensity
interfered to some extent with activity, sleep, and mood, with-
out signiﬁcant difference between groups. The delayed onset of
neuropathic pain after breast surgery could be explained by a
mixed nature of pain (nociceptive and neuropathic) associated
with surgery. The higher nociceptive pain intensity may hide
the less neuropathic pain sensation at the beginning. But after
a few days, nociceptive type of pain resolved by tissue healing,
while nerves needed longer time to recover and continued
sending messages to higher centers. Therefore, patients started
to be aware with it [24].
A large number of patients (72.1%) in both groups had per-
sisting neuropathic pain in the arm up to 9 months, postoper-
atively. In consistence with the present result, Tasmuth et al.
[32] reported that most women that underwent mastectomy
or conservative breast surgery with axillary clearance had mild
to moderate neuropathic pain in the breast area or ipsilateral
arm, a month after surgery. One year after conservative breast,
82% of women were still complaining of neuropathic pain.
Eighty percent of those women reported parathesia in breast
area, while all patients reported ipsilateral arm parathesia.
Although the intensity of neuropathic pain in the present
study did not show signiﬁcant difference between the groups
1 month after surgery, the degree of unpleasantness, sensitive
and hot pain sensation were reduced signiﬁcantly under the
inﬂuence of multimodal balanced anaesthesia. Three earlier
studies evaluated PVB combined GA versus GA alone, on
the development of chronic postoperative pain. They con-
cluded that PVB lowered the prevalence and intensity of
chronic pain at1, 2, 6 and 12 months after breast surgery for
cancer [33–35].
In the current study, 3 months after surgery and 2 months
after taking gabapentin, global neuropathic pain intensity, it-
chy, dull and sharp pain reduced signiﬁcantly in the interven-
tion group. After 6 months postoperatively, most of
neuropathic pain items were inﬂuenced positively in the inter-
vention group. At 9 months, hot and superﬁcial sensations
were less in intervention group. Deep pain was not affected
either by paravertebral block or gabapentin at any time ofmeasurement. The mechanism of gabapentin-induced analge-
sia could be attributed to inhibition of calcium currents that
reduce neurotransmitter release and attenuate postsynaptic
excitability [36].
Earlier studies supported the result of the current study and
reported that, gabapentin and pregabalin reduced postopera-
tive neuropathic pain intensity [37,38]. The efﬁcacy of gaba-
pentin in reducing pain intensity and burning sensation after
4 weeks treatment in patients with spinal cord injury was re-
ported by Tai et al. [39].
The inhibitory effect of gabapentin on pain sensitivity (sen-
sation of raw skin or sun burn) that made skin over the af-
fected area very painful on touch may be similar to its effect
on tactile allodynia in a previous study [40]. The authors eval-
uated the differences between two types of tactile allodynia
(static and dynamic allodynia) in mice with herpetic or post
herpetic pain and documented that gabapentin markedly
inhibited both static and dynamic allodynia, at herpetic and
post herpetic periods.
Levendoglu et al. [41] evaluated the effect of gabapentin on
20 patients with neuropathic spinal cord injury-related pain
and found that, gabapentin reduced signiﬁcantly global pain
intensity and unpleasantness, as well as sharp, hot, deep, and
surface pain, at 4 and 8 weeks. But unlike the present ﬁnding,
they reported that gabapentin did not inﬂuence dull, sensitive,
or itchy pain. The effect of gabapentin (1800 mg) on post her-
petic neuropathic pain condition was evaluated by Jensen et al.
[42]. They reported that a signiﬁcant effect was documented on
sharp, dull, sensitive, and itchy pain. Few effects were found
on hot, cold, deep or surface pain qualities.z
The discrepancy of the efﬁcacy of gabapentin in different
pain condition may be explained by the fact that different neu-
ropathic pain characters may arise as a result of different neu-
ropathic pain conditions. Sharp, superﬁcial, sensitive and itchy
pain may be mostly obvious in peripheral neuropathy, while
deep pain is the key component of neuropathic pain after
amputation or osteoarthritis [43–45]. Gabapentin in the pres-
ent study attenuated most of neuropathic pain characters,
whereas it did not inﬂuence deep pain which may arise from
interference with lymphatic system of the breast and ipsilateral
arm after breast surgery and radiotherapy for cancer [46].
Table 6 Correlations between pain unpleasantness, pain
intensity, nitric oxide and interleukin 1-b at different times,
after breast surgery.
Times Pain mediators Pain unpleasantness Pain intensity
1 month NO 0.11 0.11
IL 1-b 0.12 0.08
3 months NO 0.29 0.29
IL 1-b 0.40** 0.45**
6 months NO 0.06 0.03
IL 1-b 0.50*** 0.58***
9 months NO 0.06 0.10
IL 1-b 0.25 0.54***
Values are correlation coefﬁcients.
** p< 0.01.
*** p< 0.001.
The effect of multimodal balanced anaesthesia and long term gabapentin 75The current study showed that, signiﬁcantly less NO and
IL-1b readings were found in intervention group in compari-
son to the control group. For NO, signiﬁcant less values were
detected after 1 and 3 months in patients experiencing less pain
intensity under the inﬂuence of PVB and gabapentin treat-
ment. Meanwhile, IL-1b median values were signiﬁcantly less
in the intervention group through the different times. A signif-
icant direct correlation between pain unpleasantness and pain
intensity and IL-1b at 3, 6 and 9 months postoperatively, was
also detected. However, there was no correlation with NO.
The presence of high levels of NO in chronic pain condi-
tions was documented in previous studies [47,48]. The attenu-
ated effect of PVB on NO release after breast surgery was
investigated by Iohom et al. [33]. They concluded that, NO val-
ues 48 h postoperatively were greater in patients receiving a
standard intraoperative and postoperative analgesic regimen
(morphine sulfate, diclofenac, dextropropoxyphene hydrochlo-
ride and acetaminophen) compared with those receiving a
continuous PVB (for 48 h), acetaminophen and parecoxib (fol-
lowed by celecoxib up to 5 days). Lower levels of NO under the
effect of gabapentin was reported by Oka et al. [49]. They
showed that gabapentin inhibited Ca2+ channels involving
the activation of NO synthetase that in turn reduced NO
production.Do you have any abnormal sensation (burning,
tingling, numbness, or soreness) that could
bother you as a result of your breast surgery?
Yes
When did this sensation commerce after your surgery? Days
Where is the site of your pain? In my b
Duration of pain Seconds
Precipitating factors Not at
Physical activity
Weighting heavy objects
Hot weather
Cold weather
How much your pain interferes with work (scale 0-4)? Not at
With Sleep, (scale 0-4)? Not at
With Mood (scale 0-4)? Not atElevated serum concentrations of anti-inﬂammatory cyto-
kines in patients with chronic pain conditions, such as juvenile
rheumatoid arthritis [50], ﬁbromyalgia [51], cervicogenic head-
ache [52], or migraneurs [53] were detected in previous studies.
Koch et al. [54] investigated a number of cytokines and
NO in the plasma of chronic pain patients (neuropathic, noce-
ciptive and mixed pain conditions) and found that pro-inﬂam-
matory cytokines (IL-1b, IL-2, IL-6, IFN-g and TNF-a)
correlated with increasing pain intensity and that plasma levels
of NO increased signiﬁcantly in patients with chronic pain.
Similarly, correlations between tissue levels of cytokines and
a number of painful conditions were detected in some studies
[55,56].
The relationship between NO release and IL-1b was not
exactly clear. Few studies examined the effect of NO on pro-
inﬂammatory cytokines. One study evaluated pain in human
immunodeﬁciency virus-1 (HIV-1) and reported that, HIV-
1stimulated pro-inﬂammatory cytokine-mediated pain was
carried out through activation of n-NOS [57]. Another study
showed that NO may facilitate the hyperalgesia induced by
pro-inﬂammatory cytokines using the cAMP second messen-
ger pathway and may also possess an independent cGMP-
dependent hyperalgesic effect [58]. Chen et al. [59] reported
that intraperitoneal injection of NOS inhibitors attenuated
thermal hyperalgesia induced by intraplantar injection of
hyperalgesic substance (complete Freund’s adjuvant) in mice.
They also concluded that pretreatment with NOS inhibitors
prevented the increased TNF and IL-1b values under the inﬂu-
ence of inﬂammatory stimulus.
Taken together, data of the present study showed that
breast surgery for cancer was associated with acute neuro-
pathic pain in 100% of the cases. This pain continued at ipsi-
lateral arm in 72.1% of the cases for 9 months following
surgery. Multimodal balanced anaesthesia in the form of
PVB in combination with GA had positive impact on acute
nociceptive and neuropathic pain. Gabapentin reduced almost
all neuropathic pain qualities with exception of deep pain. Ni-
tric oxide did not correlate with neuropathic pain intensity or
unpleasantness; however IL-1b showed a good correlation.
Further studies are required to reveal the role played by neu-
ropathic pain mediators (NO and IL-1b) in an attempt to
develop a better therapeutic strategy towards pain control.Appendix A. Questionnaire for evaluation of neuropathic painNo
Weeks Months
reast In my arm Axilla
Minutes Hours Days
all A little To some extent A lot
all A little To some extent A lot
all A little To some extent A lot
all A little To some extent A lot
76 S. Elkaradawy et al.Appendix B. Neuropathic pain scale. .
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